NEW YORK, January 11, 2022– (COMMERCIAL THREAD) –BTIG announced today that Mikhail Keyserman, CMT, CFTe, has transitioned to the company’s Healthcare Investment Banking division. In his new role as Managing Director and Biotech Specialist, he will focus on identifying investment banking and capital market opportunities in the biotech industry. Mr. Keyserman will be based in the firm’s New York office and will report directly to KC Stone, Managing Director, Head of BTIG Healthcare Investment Banking.
Healthcare investment banking continues to be a key area of interest at BTIG. The company has seen a noticeable increase in healthcare transaction flow and has a very active pipeline of transactions to execute on behalf of private and public companies in 2022.
“Since joining the company, Mikhail has leveraged his close relationships with corporate leadership teams and institutional investors across the spectrum of capital markets to drive adoption of our healthcare platform. “, commented Matt Clark, Managing Director, Head of Investment Bank BTIG. “We are very excited about the energy and expertise Mikhail will bring to our healthcare banking practice and look forward to his contributions. “
Prior to assuming his new role with the company, Mr. Keyserman was Managing Director and Senior Specialist in Healthcare Strategy and Franchise Sales at BTIG. As a member of BTIG’s Franchise Sales unit, he focused on building relationships with CIOs, portfolio managers and analysts, coming up with actionable business ideas, promoting the access program to company businesses and generating feedback on healthcare sales. Mr. Keyserman has 15 years of industry experience in a number of healthcare-focused investment and trading roles. Before BTIG, he was a partner at Nexthera Capital. Previously, Mr. Keyserman was Chief Trader at Millennium Partners. He has also held equity research, healthcare specialist and trading positions at Leerink Partners and Citi.
“I have worked closely with Mikhail in his role as senior healthcare strategy and franchise sales specialist within the firm and I believe his biotechnology expertise will be very useful to our practice,” commented Mr. Pierre.
BTIG Investment Banking’s expertise covers the consumer, energy and infrastructure, finance, healthcare, real estate as well as technology, media and telecommunications sectors. The company’s banking products include mergers and acquisitions, capital markets advice, IPOs, trailing offerings, ATMs, PSPCs, private placements, convertibles, debt buybacks and companies. Clients benefit from actionable market insight and BTIG’s comprehensive understanding of financial dynamics. After-sales services include negotiation, access to businesses, as well as proprietary research and strategy products.
BTIG is a global financial services company specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global presence and more than 700 employees, BTIG, LLC and its subsidiaries operate in 19 cities in the United States, Europe, Asia and Australia. BTIG offers execution, expertise and information on equities, equity derivatives, ETFs and fixed income securities, currencies and commodities (futures, interest rates, credit and convertible and preferred securities) . The company’s core capabilities include global execution, portfolio, electronic and outsourced trading, transition management, investment banking, blue chip brokerage, introduction of capital, access to business, research and strategy, commission management and more.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220111005703/en/